Results 21 to 30 of about 5,953 (226)

VIROLOGICAL RESPONSES OF VELPATASVIR/SOFOSBUVIR IN PATIENTS WITH HCV GENOTYPE 3

Journal of University Medical & Dental College, 2020
BACKGROUND & OBJECTIVE: The role of Velpatasvir/Sofosbuvir in the treatment of hepatitis C virus type 3 infection is evaluated in terms of virologic responses. i.e Rapid Virological Response (RVR) End of treatment response (ETR) and Sustained virological
Muhammad Sarfraz, Arshad Rabbani
doaj   +1 more source

Real‐world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes

JGH Open, 2023
Background and Aim Sofosbuvir–velpatasvir was recommended for subsidy to treat chronic hepatitis C in Singapore in 2018. We measured the impact of the subsidy decision on clinical practice and patient outcomes.
Chee‐Kiat Tan, Xue‐Shi Luo, Benjamin Shao‐Kiat Ong, Liang Lin, Kwong‐Hoe Ng   +4 more
doaj   +1 more source

Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. [PDF]

, 2016
There have been dramatic advancements in the treatment of chronic hepatitis C (HCV) infection. This is largely due to the approval of several direct-acting antiviral agents (DAAs) from a variety of medication classes with novel mechanisms of action ...
Bidell, Monique R, Faragon, John, McLaughlin, Milena, Morse, Caroline, Patel, Nimish   +4 more
core   +2 more sources

Hepatitis C virus resistance to the new direct-acting antivirals [PDF]

, 2016
Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in recent years with the widespread use of interferon-free combination regimens.
Esposito, Isabella, Soriano, Vicente, Trinks, Julieta   +2 more
core   +1 more source

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection [PDF]

, 2015
published_or_final_versio
Abergel, A, Agarwal, K, Asselah, T, Brainard, DM, Chan, HLY, Feld, JJ, Gruener, N, Hézode, C, Jacobson, IM, Lai, CL, Mangia, A, Mazzotta, F, McHutchison, JG, McNally, J, Moreno, C, Osinusi, A, Ruane, PJ, Shafran, SD, Svarovskaia, E, Towner, WJ, Tran, TT, Yoshida, E, Zeuzem, S, Zhu, Y   +23 more
core   +1 more source

Efficacy of Sofosbuvir-Velpatasvir-Ribavirin Regimen for Retreatment of Chronic Hepatitis C in Patients With Prior DAA Failure: A Retrospective Study From a National Treatment Center. [PDF]

Int J Hepatol
Singh S, Sengupta S, Kumar D, Mukherjee K, Hasan AMD, Sadhukhan P, Ahammed SM.   +6 more
europepmc   +3 more sources

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY):an open-label, single-arm, phase 4, multicentre trial [PDF]

, 2018
BACKGROUND Despite revised guidelines that no longer exclude people who inject drugs (PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to treat recent PWID.
Alavi, Artenie, Asher, Aspinall, Barua, Cunningham, Darke, Degenhardt, Dore, Dore, Dore, Feld, Foster, Grebely, Grebely, Grebely, Grebely, Grebely, Grebely, Hajarizadeh, Islam, Islam, Lalezari, Lamoury, Marshall, Martin, Martin, Mason, Midgard, Morris, Nelson, Read, Robaeys, Robaeys, Scott, Simmons, Sulkowski, Young   +37 more
core   +3 more sources

Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).

PLoS ONE, 2023
BackgroundHepatitis C virus (HCV) is a common cause of liver cirrhosis and hepatocellular carcinoma. Globally, nearly 71 million people have chronic HCV infection, and approximately 399,000 dies annually.
Ashish Awasthi, Harshita Katiyar, Sumit Rungta, Amar Deep, Vinod Kumar, Shalimar, Ajay Kumar, Prachi Tiwari, Amit Goel   +8 more
doaj   +1 more source

Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies [PDF]

, 2018
[Abstract] The presence of resistance‐associated substitutions (RASs) at NS5A region might compromise the efficacy of Direct Acting Antiviral agents (DAAs).
Bagaglio, Black, Calleja, Chen, Dietz, Foster, Kalaghatgi, Lindström, Nelson, Palladino, Paolucci, Pawlotsky, Plaza, Poveda, Poveda, Pérez, Sarrazin, Wyles, Zeuzem, Zeuzem, Zeuzem   +20 more
core   +2 more sources

Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs

PLoS ONE, 2023
Background Insurers manage the cost of specialty medicines via rebates, however it is unclear if the savings are passed on to patients, and whether reducing rebates may lead to changes in patient out-of-pocket (OOP) costs and medication adherence.
William Bruce Wong, Arpamas Seetasith, Anna Hung, Leah L. Zullig   +3 more
doaj   +3 more sources